Cialis Related Published Studies
Well-designed clinical trials related to Cialis (Tadalafil)
Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. [2011.11.15]
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. [2011.11]
Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. [2011.09]
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. [2011.07]
Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound. [2011.07]
[Efficacy and safety of long-term small-dose tadalafil in the treatment of erectile dysfunction]. [2011.06]
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. [2011.06]
Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. [2011.05]
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. [2011.04]
Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. [2011.03]
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. [2011.01]
Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). [2011.01]
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. [2010.12]
Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. [2010.10]
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. [2010.06]
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. [2010.06]
Tadalafil: in pulmonary arterial hypertension. [2010.03.05]
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. [2010.03]
Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. [2010.03]
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. [2010.02]
Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. [2010.01]
Impact of tadalafil once daily in men with erectile dysfunction--including a
report of the partners' evaluation. [2010]
Tadalafil: in pulmonary arterial hypertension. [2010]
Urodynamic effects of once daily tadalafil in men with lower urinary tract
symptoms secondary to clinical benign prostatic hyperplasia: a randomized,
placebo controlled 12-week clinical trial. [2010]
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]
[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil] [2009.11]
Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis. [2009.10]
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. [2009.10]
[Chronic PDE-5 inhibition in patients with erectile dysfunction : New treatment approach using once daily Tadalafil.] [2009.09.09]
Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. [2009.08.15]
Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. [2009.07]
Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. [2009.07]
Tadalafil therapy for pulmonary arterial hypertension. [2009.06.09]
Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. [2009.05]
Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. [2009.04.22]
Retinal effects of 6 months of daily use of tadalafil or sildenafil. [2009.04]
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
Effect of tadalafil on blood flow, pain, and function in chronic cold Complex Regional Pain Syndrome: a randomized controlled trial. [2008.10.20]
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. [2008.10]
Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. [2008.09]
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. [2008.05]
Effect of tadalafil on anaerobic performance indices in healthy athletes. [2008.02]
Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. [2008.01]
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. [2008]
Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. [2007.12]
Efficacy and Safety of Tadalafil in Men With Erectile Dysfunction Following Spinal Cord Injury. [2007.09.10]
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. [2007.07]
Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy. [2007.05]
A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. [2007.05]
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2007.04]
The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. [2007.04]
Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. [2006.11]
Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. [2006.10.03]
A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. [2006.10.01]
Through the eyes of women: the partners' perspective on tadalafil. [2006.09]
Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. [2006.08]
Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. [2006.07]
Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. [2006.06]
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. [2006.06]
Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries. [2006.05]
Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. [2006.05]
Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. [2006.04]
[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study] [2006.01]
An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. [2005.12]
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. [2005.09]
Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. [2005.09]
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. [2005.08.16]
An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. [2005.06]
Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. [2005.05]
A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. [2005.02]
Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. [2005.02]
Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. [2005.02]
Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. [2005.01]
Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. [2004.11]
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. [2004.11]
Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients. [2004.11]
Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. [2004.10]
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. [2004.10]
Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. [2004.09]
Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. [2004.09]
Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. [2004.09]
Population dose-response model for tadalafil in the treatment of male erectile dysfunction. [2004.08]
The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. [2004.08]
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. [2004.04]
Time course of the interaction between tadalafil and nitrates. [2003.11.19]
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. [2003.11]
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. [2003.09]
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. [2003.07]
Effects of tadalafil on erectile dysfunction in men with diabetes. [2002.12]
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. [2002.10]
On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. [2001.02]
Well-designed clinical trials possibly related to Cialis (Tadalafil)
Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. [2011.11]
Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. [2011.06.15]
Effect on sexual function of a vacuum erection device post-prostatectomy. [2011.06]
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. [2011.06]
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. [2011.04]
The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study. [2011.01]
Minimal clinically important differences in the erectile function domain of the
International Index of Erectile Function scale. [2011]
Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. [2010.01]
Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders. [2010]
Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. [2009.11.03]
|
